Chugai Pharmaceutical stock: Q2 revenue hits JPY 341.58 billion, value JPY 10.58 trillion

Published on 10/20/2026 at 16:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Half-year revenue reached JPY 663.33 billion in 2026. Chugai Pharmaceutical stock costs EUR 36.19 on October 20, 2026 versus Frankfurt.

Q2 revenue and valuation

Chugai reported JPY 341.58 billion in second-quarter revenue on July 27, 2026.
Half-year revenue reached JPY 663.33 billion, up from JPY 578.46 billion a year earlier.
Chugai Pharmaceutical stock costs EUR 36.19 at Lang & Schwarz on October 20, 2026 at 4:05 p.m. CEST, 2.81 percent above the Frankfurt close of October 19, 2026.
Chugai trades at a P/E ratio of 22.45 with a JPY 10.6 trillion market capitalization.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) reported second-quarter revenue of JPY 341.58 billion for 2026, while its JPY 10.6 trillion market value keeps valuation in view. The figure was reported on July 27, 2026 by JPX Market Explorer. The stock was trading at EUR 36.19 at Lang & Schwarz on October 20, 2026 at 4:05 p.m. CEST, 2.81 percent above the Frankfurt close of October 19, 2026 at EUR 35.20.

Revenue growth remains measurable

Chugai's second-quarter revenue rose from JPY 291.58 billion a year earlier to JPY 341.58 billion, an increase of 17.14 percent. The same report put net income at JPY 116.33 billion, while the company's half-year revenue reached JPY 663.33 billion versus JPY 578.46 billion in the first half of 2025, a gain of 14.67 percent.

The improvement is not limited to sales. JPX Market Explorer reported half-year net income of JPY 231.75 billion, up from JPY 194.39 billion a year earlier, while diluted earnings per share rose to JPY 140.82 from JPY 118.12.

Tokyo valuation sets the frame

Chugai's Tokyo Stock Exchange quotation stood at JPY 6,430 on October 20, 2026 at 3:30 p.m. JST, after the market closed. The same quotation showed a P/E ratio of 22.45, market capitalization of JPY 10.58 trillion and volume of 2,458,600 shares.

That valuation sits between two large Japanese pharmaceutical peers. Shionogi & Co. traded at JPY 2,978.50 with a P/E ratio of 9.62 and a JPY 2.5 trillion market value, while Daiichi Sankyo traded at JPY 2,820 with a P/E ratio of 21.36 and a JPY 5.1 trillion market value on October 20, 2026.

What dates matter for investors?

Chugai Pharmaceutical lists two events for October 27, 2026: the fiscal 2026 third-quarter results at 5:00 p.m. JST and the results conference at 6:00 p.m. JST. The scheduled release covers January through September 2026 and will provide the next period comparison.

The latest completed half-year figures give investors a concrete benchmark before those events. Revenue growth of 14.67 percent and net-income growth of 19.01 percent provide the operating backdrop, while the P/E ratio of 22.45 leaves the share price sensitive to execution against the company's earnings path.

Chugai stock and peers

Chugai Pharmaceutical: 2.81 percent above the Frankfurt close, P/E 22.45, market capitalization JPY 10.6 trillion

Shionogi & Co. (Tokyo Stock Exchange, JPY): 1.34 percent higher, P/E 9.62, market capitalization JPY 2.5 trillion

Daiichi Sankyo (Tokyo Stock Exchange, JPY): 2.19 percent higher, P/E 21.36, market capitalization JPY 5.1 trillion

Stock price and next signal

Chugai combines double-digit half-year revenue growth with a valuation above Shionogi's and close to Daiichi Sankyo's. The next scheduled results on October 27, 2026 will add the third-quarter operating figures.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.